Los Angeles Capital Management LLC Has $1.27 Million Position in Organon & Co. (NYSE:OGN)

Los Angeles Capital Management LLC reduced its stake in shares of Organon & Co. (NYSE:OGN) by 67.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 85,322 shares of the company’s stock after selling 174,509 shares during the quarter. Los Angeles Capital Management LLC’s holdings in Organon & Co. were worth $1,273,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Commerce Bank grew its stake in shares of Organon & Co. by 5.5% during the third quarter. Commerce Bank now owns 12,168 shares of the company’s stock worth $233,000 after purchasing an additional 637 shares during the period. MassMutual Private Wealth & Trust FSB boosted its holdings in Organon & Co. by 32.4% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 2,749 shares of the company’s stock worth $41,000 after buying an additional 672 shares during the last quarter. Graypoint LLC grew its position in shares of Organon & Co. by 6.2% during the 3rd quarter. Graypoint LLC now owns 14,555 shares of the company’s stock worth $278,000 after buying an additional 853 shares during the period. CIBC Asset Management Inc increased its stake in shares of Organon & Co. by 4.9% in the 4th quarter. CIBC Asset Management Inc now owns 25,523 shares of the company’s stock valued at $381,000 after acquiring an additional 1,184 shares during the last quarter. Finally, Deseret Mutual Benefit Administrators raised its position in shares of Organon & Co. by 24.3% in the 4th quarter. Deseret Mutual Benefit Administrators now owns 6,256 shares of the company’s stock valued at $93,000 after acquiring an additional 1,222 shares during the period. 77.43% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on OGN shares. TD Cowen upgraded shares of Organon & Co. to a “hold” rating in a report on Wednesday, January 15th. Barclays reduced their price target on shares of Organon & Co. from $26.00 to $24.00 and set an “overweight” rating on the stock in a research report on Friday, February 14th. Finally, Morgan Stanley lowered their price objective on shares of Organon & Co. from $17.00 to $16.00 and set an “equal weight” rating for the company in a research report on Friday, February 14th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, two have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $20.80.

Organon & Co. Stock Performance

OGN opened at $14.91 on Friday. The company has a market capitalization of $3.84 billion, a price-to-earnings ratio of 4.48, a P/E/G ratio of 0.90 and a beta of 0.76. The business’s 50-day moving average price is $15.44 and its two-hundred day moving average price is $17.12. Organon & Co. has a 1 year low of $13.87 and a 1 year high of $23.10. The company has a debt-to-equity ratio of 17.73, a current ratio of 1.70 and a quick ratio of 1.21.

Organon & Co. (NYSE:OGN) last announced its quarterly earnings data on Thursday, February 13th. The company reported $0.83 earnings per share for the quarter, missing the consensus estimate of $0.92 by ($0.09). Organon & Co. had a net margin of 13.49% and a return on equity of 431.62%. The company had revenue of $1.59 billion during the quarter, compared to the consensus estimate of $1.57 billion. Equities analysts expect that Organon & Co. will post 3.68 EPS for the current fiscal year.

Organon & Co. Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 13th. Stockholders of record on Monday, February 24th will be paid a dividend of $0.28 per share. The ex-dividend date is Monday, February 24th. This represents a $1.12 annualized dividend and a dividend yield of 7.51%. Organon & Co.’s dividend payout ratio is presently 33.63%.

Organon & Co. Company Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.